Portfolio – Open Trials

Quality of Life After Radiotherapy Treatment For Patients With Stage IV Non-Small Cell Lung Cancer

International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma

A randomised open-label phase III trial of Reduced Frequency pembrolizumab immuNothErapy for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design

A randomised open-label phase III trial of Reduced Frequency pembrolizumab immunotherapy for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design

A randomised phase II trial of investigator choice standard therapy versus sequential novel therapy experimental arms in relapsed and refractory follicular lymphoma

Secured Access to innovative medicines for CHildren, adolescents and young adults
with cAncer

Open label randomised controlled trial of intensive surveillance vs. standard postoperative follow-up in patients undergoing surgical resection for oesophageal and gastric cancer

An International clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma

A Phase III, randomised, multi-centre trial addressing overtreatment of small screen-detected breast cancer by comparing standard surgery versus minimally invasive vacuum-assisted excision

A phase II, randomiSed study of CHOP-R in combination with acalabruTinib comparEd to CHOP-R in patients with newLy diagnosed Richter’s Syndrome and a pLAtfoRm for initial investigations into activity of novel treatments in relapsed/refractory and newly diagnosed Richter’s Syndrome

A Phase 2, Open-Label, Randomised Study To Evaluate Prophylactic Interventions On Talquetamab-Related Oral Toxicity

Tumour Characterization to Guide Experiential Targeted Therapy – National

Thoracic Umbrella Radiotherapy Study In Stage IV NSCLC

Thoracic Umbrella Radiotherapy Study in stage IV NSCLC

A Cancer Research UK Phase II open label trial in participants with metastatic pancreatic ductal adenocarcinoma of ginisortamab given intravenously with i) first-line standard of care nab-paclitaxel and gemcitabine, or ii) in combination with MEK inhibitor maintenance therapy